Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus NICARDIPINE HYDROCHLORIDE IN 0 86 SODIUM CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus NICARDIPINE HYDROCHLORIDE IN 0 86 SODIUM CHLORIDE.
MAGNESIUM SULFATE vs NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes, leading to vasodilation and reduced myocardial contractility.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
Intravenous infusion: initial rate 5 mg/hour, titrate by 2.5 mg/hour every 15 minutes as needed up to 15 mg/hour. For acute hypertension, 5 mg/hour initial, increase by 2.5 mg/hour every 5-15 minutes to maximum 15 mg/hour.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateTerminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Terminal elimination half-life is 2 to 4 hours; prolonged in hepatic impairment or with continuous infusion.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 35% of metabolites.
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."